Length of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitis

Eur J Gastroenterol Hepatol. 2014 Nov;26(11):1240-6. doi: 10.1097/MEG.0000000000000187.


Background: Cyclosporine and infliximab (IFX) seem equally effective as rescue therapy in hospitalized patients with severe ulcerative colitis (UC), although associated hospital stay and costs may differ.

Aim: The aim of this study was to compare the duration of hospital stay and associated costs from initiation of rescue therapy to time of discharge in hospitalized patients with corticosteroid-refractory UC receiving cyclosporine or IFX. Colectomy rates after 6 months were used as the outcome parameter for treatment success.

Patients and methods: Hospital records of patients admitted between November 2003 and August 2012 at a tertiary referral center were analyzed.

Results: Forty-two patients were included (cyclosporine group: 26 patients; IFX group: 16 patients). Patient characteristics were comparable, with the exception that cyclosporine-treated patients more often had a pancolitis (89 vs. 63%, P=0.046). The median length of hospital stay was 11.0 (interquartile range 7.75-13.25) versus 4.0 days (interquartile range 4.0-5.75) in the cyclosporine and IFX group (P<0.01), respectively. The mean in-hospital costs were significantly higher in the cyclosporine-treated versus IFX-treated patients (6121 vs. 4853 euros, P<0.05), whereas the total costs up to 3 months after initiation of rescue therapy were significantly higher in the IFX group (6787 vs. 9983 euros, P<0.01). There were no significant differences in colectomy rates at 6 months (23 and 31% for cyclosporine and IFX, P=0.50). More side-effects were observed during treatment with cyclosporine.

Conclusion: Length of hospital stay and in-hospital costs have been reduced significantly since the introduction of IFX as rescue therapy for severe UC instead of cyclosporine. However, the total treatment costs are higher in IFX-treated patients.

MeSH terms

  • Adult
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / economics
  • Antibodies, Monoclonal / therapeutic use*
  • Colectomy / statistics & numerical data
  • Colitis, Ulcerative / drug therapy*
  • Colitis, Ulcerative / economics
  • Colitis, Ulcerative / surgery
  • Cyclosporine / adverse effects
  • Cyclosporine / economics
  • Cyclosporine / therapeutic use*
  • Drug Costs / statistics & numerical data
  • Female
  • Gastrointestinal Agents / adverse effects
  • Gastrointestinal Agents / economics
  • Gastrointestinal Agents / therapeutic use
  • Health Services Research / methods
  • Hospital Costs / statistics & numerical data*
  • Hospitalization / statistics & numerical data
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / economics
  • Immunosuppressive Agents / therapeutic use
  • Infliximab
  • Kaplan-Meier Estimate
  • Length of Stay / economics
  • Length of Stay / statistics & numerical data*
  • Male
  • Netherlands
  • Treatment Outcome
  • Young Adult


  • Antibodies, Monoclonal
  • Gastrointestinal Agents
  • Immunosuppressive Agents
  • Cyclosporine
  • Infliximab